Literature DB >> 11221846

Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.

P M Pollock1, J Welch, N K Hayward.   

Abstract

Cytogenetic and loss of heterozygosity (LOH) studies have long indicated the presence of a tumor suppressor gene (TSG) on 9p involved in the development of melanoma. Although LOH at 9p has been reported in approximately 60% of melanoma tumors, only 5-10% of these tumors have been shown to carry CDKN2A mutations, raising the possibility that another TSG involved in melanoma maps to chromosome 9p. To investigate this possibility, a panel of 37 melanomas derived from 35 individuals was analyzed for CDKN2A mutations by single-strand conformation polymorphism analysis and sequencing. The melanoma samples were then typed for 15 markers that map to 9p13-24 to investigate LOH trends in this region. In those tumors demonstrating retention of heterozygosity at markers flanking CDKN2A and LOH on one or both sides of the gene, multiplex microsatellite PCR was performed to rule out homozygous deletion of the region encompassing CDKN2A. CDKN2A mutations were found in tumors from 5 patients [5 (14%) of 35], 4 of which demonstrated LOH across the entire region examined. The remaining tumor with no observed LOH carried two point mutations, one on each allele. Although LOH was identified at one or more markers in 22 (59%) of 37 melanoma tumors corresponding to 20 (57%) of 35 individuals, only 11 tumors from 9 individuals [9 (26%) of 35] demonstrated LOH at D9S942 and D9S1748 the markers closest to CDKN2A. Of the remaining 11 tumors with LOH 9 demonstrated LOH at two or more contiguous markers either centromeric and/or telomeric to CDKN2A while retaining heterozygosity at several markers adjacent to CDKN2A. Multiplex PCR revealed one tumor carried a homozygous deletion extending from D9S1748 to the IFN-alpha locus. In the remaining eight tumors, multiplex PCR demonstrated that the observed heterozygosity was not attributable to homozygous deletion and stromal contamination at D9S1748, D9S942, or D9S974, as measured by comparative amplification strengths, which indicates that retention of heterozygosity with flanking LOH does not always indicate a homozygous deletion. This report supports the conclusions of previous studies that a least two TSGs involved in melanoma development in addition to CDKN2A may reside on chromosome 9p.

Entities:  

Mesh:

Year:  2001        PMID: 11221846

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

2.  Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Authors:  Laura Thomas; Lan Kluwe; Nadia Chuzhanova; Victor Mautner; Meena Upadhyaya
Journal:  Neurogenetics       Date:  2010-04-01       Impact factor: 2.660

3.  Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations.

Authors:  David M Roy; Logan A Walsh; Alexis Desrichard; Jason T Huse; Wei Wu; JianJiong Gao; Promita Bose; William Lee; Timothy A Chan
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

4.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

5.  Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Authors:  David A Solomon; Jung-Sik Kim; Julia C Cronin; Zita Sibenaller; Timothy Ryken; Steven A Rosenberg; Habtom Ressom; Walter Jean; Darell Bigner; Hai Yan; Yardena Samuels; Todd Waldman
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.

Authors:  Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

7.  Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer.

Authors:  Zhihong Shan; Tracy Parker; Jonathan S Wiest
Journal:  Oncogene       Date:  2004-08-26       Impact factor: 9.867

8.  Effects of exogenous p16(ink4a) gene on biological behaviors of human lung cancer cells.

Authors:  Xiaoju Zhang; Yang Jin; Xiaonan Tao; Ming Bai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

9.  The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.

Authors:  Selvaraju Veeriah; Cameron Brennan; Shasha Meng; Bhuvanesh Singh; James A Fagin; David B Solit; Philip B Paty; Dan Rohle; Igor Vivanco; Juliann Chmielecki; William Pao; Marc Ladanyi; William L Gerald; Linda Liau; Timothy C Cloughesy; Paul S Mischel; Chris Sander; Barry Taylor; Nikolaus Schultz; John Major; Adriana Heguy; Fang Fang; Ingo K Mellinghoff; Timothy A Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-28       Impact factor: 11.205

10.  Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.

Authors:  Shyama Majumdar; Edward M Gong; Dolores Di Vizio; Jonathan Dreyfuss; David J Degraff; Martin H Hager; Peter J Park; Joaquim Bellmunt; Robert J Matusik; Jonathan E Rosenberg; Rosalyn M Adam
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.